Enrollment of 80mg PK Run-In Cohort in Ph 2 EVANGELINE Trial of (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer Completed
“Full enrollment of the 80mg pharmacokinetic run-in cohort of the EVANGELINE study is yet another important milestone in our ambitious (Z)-endoxifen development program,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “Based on data from the 40mg cohort and a review of safety, efficacy and PK data from participants enrolled earlier in the 80mg PK run-in cohort, we are confident that the 80mg dose will be well tolerated and deliver the optimal concentration levels to fully target PKCβ1 inhibition. We look forward to opening the treatment arm of this important study and bringing this potentially transformative treatment to women diagnosed with breast cancer as quickly as possible.”
Share:
More News
“Between 2017 and 2023, the socioeconomic burden of HER2-positive breast cancer in ten major economies was nearly $590 billion, projected to increase to nearly $1,000 billion by 2032,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “At-home treatment may help alleviate the pressure
Richard Saynor, CEO of Sandoz, said: “The global burden of cancer continues to grow and the potential to address unmet patient needs has never been greater. This agreement offers us the chance to reach many more millions of patients, while helping to drive the long-term sustainability of healthcare systems.”
“Beyond the second-line monotherapy opportunity, we and our partners at Pfizer have removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan,” continued Dr. Houston. “This decision was made following
“The interim PFS analysis results demonstrated that, compared to the current standard treatment, KN026 in combination with chemotherapy significantly improved PFS, reduced the risk of disease progression or death, and showed a trend toward OS benefit. Detailed data from this study will be presented at an upcoming international academic conference.”
